PL2049127T3 - N-metanokarbapochodne do leczenia chorób serca - Google Patents

N-metanokarbapochodne do leczenia chorób serca

Info

Publication number
PL2049127T3
PL2049127T3 PL07777211T PL07777211T PL2049127T3 PL 2049127 T3 PL2049127 T3 PL 2049127T3 PL 07777211 T PL07777211 T PL 07777211T PL 07777211 T PL07777211 T PL 07777211T PL 2049127 T3 PL2049127 T3 PL 2049127T3
Authority
PL
Poland
Prior art keywords
cardiac diseases
treat cardiac
methanocarba derivatives
methanocarba
derivatives
Prior art date
Application number
PL07777211T
Other languages
English (en)
Inventor
Bruce Tsan Liang
Achilles Pappano
Jian-Bing Shen
Original Assignee
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut filed Critical Univ Connecticut
Publication of PL2049127T3 publication Critical patent/PL2049127T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07777211T 2006-05-23 2007-05-22 N-metanokarbapochodne do leczenia chorób serca PL2049127T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80287806P 2006-05-23 2006-05-23
US89394607P 2007-03-09 2007-03-09
PCT/US2007/012151 WO2007139775A2 (en) 2006-05-23 2007-05-22 N-methanocarba derivatives to treat cardiac diseases
EP07777211.9A EP2049127B1 (en) 2006-05-23 2007-05-22 N-methanocarba derivatives to treat cardiac diseases

Publications (1)

Publication Number Publication Date
PL2049127T3 true PL2049127T3 (pl) 2015-03-31

Family

ID=38596738

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07777211T PL2049127T3 (pl) 2006-05-23 2007-05-22 N-metanokarbapochodne do leczenia chorób serca

Country Status (7)

Country Link
US (1) US8410078B2 (pl)
EP (1) EP2049127B1 (pl)
DK (1) DK2049127T3 (pl)
ES (1) ES2526713T3 (pl)
PL (1) PL2049127T3 (pl)
PT (1) PT2049127E (pl)
WO (1) WO2007139775A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11346797B2 (en) 2002-12-20 2022-05-31 Agilent Technologies, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
AU2009231978C1 (en) 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
WO2010014921A2 (en) * 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
CA2723223C (en) 2008-05-05 2017-06-06 Acea Biosciences, Inc. Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
PT2539352T (pt) * 2010-02-22 2018-01-03 Univ Connecticut Composições e métodos para tratar doenças cardíacas
US9681836B2 (en) 2012-04-23 2017-06-20 Cyberonics, Inc. Methods, systems and apparatuses for detecting seizure and non-seizure states
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders
US10195198B2 (en) 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
CN109310695B (zh) 2016-04-21 2022-04-01 阿斯特罗赛特制药公司 治疗神经和心血管病况的化合物和方法
EP3589299B1 (en) * 2017-03-03 2025-04-09 Agilent Technologies, Inc. METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES
US11839615B2 (en) 2018-02-09 2023-12-12 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating addiction and related disorders
EP3856741A4 (en) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
USD941488S1 (en) 2020-02-07 2022-01-18 Agilent Technologies, Inc. Instrument for analyzing biological cells
US20210301245A1 (en) 2020-03-29 2021-09-30 Agilent Technologies, Inc. Systems and methods for electronically and optically monitoring biological samples
JP2026524988A (ja) * 2023-07-21 2026-07-24 コーノヴァス・ファーマシューティカルズ・インコーポレイテッド 心臓のｐ２ｘ受容体アゴニストの水性製剤及びその疾患の治療における使用
WO2025255059A1 (en) * 2024-06-03 2025-12-11 Cornovus Pharmaceuticals, Inc. Crystalline forms and salt forms of a cardiac p2x receptor agonist, pharmaceutical compositions, and their use in treating medical disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712258A (en) 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
AU1363699A (en) 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
WO2001013900A2 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
ATE336492T1 (de) 2000-01-14 2006-09-15 Us Gov Health & Human Serv Methonocarbacycloalkylanaloga von nucleosiden
KR20070050484A (ko) 2004-09-09 2007-05-15 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Ａ1 및 ａ3 아데노신 수용체 아고니스트로서의 퓨린 유도체

Also Published As

Publication number Publication date
EP2049127B1 (en) 2014-11-26
US20070281908A1 (en) 2007-12-06
ES2526713T3 (es) 2015-01-14
EP2049127A2 (en) 2009-04-22
WO2007139775A3 (en) 2008-01-24
WO2007139775A2 (en) 2007-12-06
DK2049127T3 (en) 2015-01-05
US8410078B2 (en) 2013-04-02
PT2049127E (pt) 2014-12-23

Similar Documents

Publication Publication Date Title
PT2049127E (pt) Derivados n-metanocarba para tratamento de doenças cardíacas
IL209730A0 (en) Triazole derivatives useful for the treatment of diseases
IL200368A0 (en) Treatment of diseases characterized by inflammation
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
GB0602178D0 (en) Therapeutic treatment
SI2044111T1 (sl) Ciljanje komplementa faktorja H za zdravljenje bolezni
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
PT2056863T (pt) Tratamento de doenças oculares
EP2049899A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
ZA200905364B (en) Treatment of diseases characterized by inflammation
HUE037611T2 (hu) AMP-származékok szívbetegségek kezelésére
EP2148667A4 (en) USE OF CYCLOHEXANHEXOL DERIVATIVES IN THE TREATMENT OF EYE DISEASES
IL202287A0 (en) Therapeutic pyrazolonaphthyridine derivatives
GB0608655D0 (en) Therapeutic Treatment
EP2026822A4 (en) TOPICAL TREATMENT FOR EYE SURGERY DISEASES
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2157089A4 (en) THERAPEUTIC USES OF IMIDAZOL-5-CARBOXYLIC ACID DERIVATIVES
IL213606A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflamatory skin diseases
GB0610909D0 (en) Therapeutic treatment
GB2447884B (en) Treatment for skin disease
GB0623740D0 (en) Treatment of disease
PL2160190T3 (pl) Pochodne 5beta, 14beta-androstanu przydatne w leczeniu chorób będących wynikiem zwłóknienia organu
GB0610376D0 (en) Therapeutic treatment